CHMP Maintains Refusal Of TLC's Doxorubicin

 
• By Dave Wallace

The CHMP has confirmed its negative opinion on TLC Biopharmaceuticals’ doxorubicin hybrid. Meanwhile, Accord has received two posaconazole approvals, Zentiva has withdrawn an application for ambrisentan, and the EMA has launched a review of methocarbamol/paracetamol medicines.

Refused
The CHMP’s Re-examination Confirmed Its Refusal • Source: Shutterstock

More from Regulation

More from Policy & Regulation